Related Experiment Video
Updated: Jun 16, 2026
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome
Published on: June 15, 2016
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic
Daniela Asslaber1, Josefina D Piñón, Irina Seyfried
1Laboratory for Immunological and Molecular Cancer Research, 3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectiology, Paracelsus Medical University Salzburg, Salzburg, Austria.
Abstract:
In chronic lymphocytic leukemia (B-CLL), aberrations along the p53 axis lead to decreased overall survival and therapy resistance. Recent studies identified microRNA-34a (miR-34a) as a major downstream target of p53. We monitored the expression of miR-34a during disease development in a murine B-CLL model. miR-34a was up-regulated more than 20-fold during the leukemic but not during the preleukemic phase. In the human system, B-CLL cells also had 4.6-fold higher miR-34a expression compared with B cells of healthy controls. In B-CLL cells of patients with p53 aberrations, miR-34a expression was consistently low. The broad distribution of miR-34a levels in p53 wild-type patients prompted us to study the correlation between single nucleotide polymorphism 309 (SNP309) in the intronic promoter of MDM2 and miR-34a expression. B-CLL cells of patients with the SNP309 GG genotype had significantly lower miR-34a expression levels compared with patients with the TT genotype (P = .002). Low miR-34a levels were able to predict shorter time to treatment (P = .003) and were associated with an abbreviated lymphocyte doubling time. Further, overexpression of miR-34a in primary B-CLL cells induced apoptosis. These findings suggest miR-34a as a possible therapeutic avenue and a sensitive indicator of the activity of the p53 axis in B-CLL.
Insights
MicroRNA-34a (miR-34a) is upregulated in chronic lymphocytic leukemia (B-CLL) and its low levels predict shorter time to treatment. Overexpressing miR-34a induces apoptosis, suggesting its therapeutic potential in B-CLL.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrations in the p53 pathway are linked to poor prognosis and treatment resistance in chronic lymphocytic leukemia (B-CLL).
- MicroRNA-34a (miR-34a) is a key downstream target of the p53 tumor suppressor.
- Understanding miR-34a's role in B-CLL pathogenesis is crucial for developing novel therapeutic strategies.
Purpose of the Study:
- To investigate the expression patterns of miR-34a during B-CLL development and progression.
- To explore the correlation between miR-34a levels, p53 pathway status, and clinical outcomes in B-CLL patients.
- To assess the therapeutic potential of miR-34a in B-CLL.
Main Methods:
- Monitoring miR-34a expression in a murine B-CLL model during different disease phases.
- Quantifying miR-34a expression in human B-CLL cells and comparing it to healthy controls.
- Analyzing the association between miR-34a levels, p53 aberrations, and the MDM2 SNP309 genotype.
- Evaluating the impact of miR-34a overexpression on apoptosis in primary B-CLL cells.
Main Results:
- miR-34a expression was significantly upregulated during the leukemic phase in a murine model and in human B-CLL cells compared to controls.
- B-CLL cells with p53 aberrations exhibited consistently low miR-34a levels.
- Patients with the MDM2 SNP309 GG genotype showed lower miR-34a expression than those with the TT genotype.
- Low miR-34a levels correlated with shorter time to treatment and faster lymphocyte doubling time.
- Overexpression of miR-34a induced apoptosis in B-CLL cells.
Conclusions:
- miR-34a is dysregulated in B-CLL and its expression is linked to p53 pathway activity.
- Low miR-34a levels serve as a predictive biomarker for disease progression and treatment needs in B-CLL.
- miR-34a represents a promising therapeutic target for B-CLL treatment.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
02:23Abnormal Proliferation